Companies / Kuwait
Hikma Reports Strong First Half
September 2006 | Company Finance AlertJordan-based generic drugmaker Hikma Pharmaceuticals has unveilled a 9.5% increase in profits for H106, driven by strong revenue growth for is branded and injectable drug businesses. Profits reached US$42.4mn in the reporting period, compared to a figure of US$38.7mn for H105. Meanwhile, revenues also posted strong growth, rising 17.6% to
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
